Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Comment by HomerAndCompanyon Oct 26, 2021 9:08am
97 Views
Post# 34048799

RE:Anyone following the strategy in the background ?

RE:Anyone following the strategy in the background ?Another great post MrMugsy!

Profound's strategy of more aggressive expansion of recurring non-capital revenue in the US is bound to benefit from partner Akumin's own aggressive expansion. It can only be a positive for Profound, maybe a huge positive.

Might the potential Akumin sees in treatment of prostate conditions with TULSA-PRO have provided some impetus to expand?

Do you know how big Akumin was before in terms of states, hospitals and clinics? 

MrMugsy wrote: So Profound has partnered with RadNet and Akumin Inc on the imaging centers side of things.

Akumin recently made a blockbuster acquisition (Alliance Healthcare Services).

As I understand it ... Akumin is now in 46 states, partnered with over 1,000 hospitals and has 188 imaging and radiation therapy clinics (as of September 2021).

One small problem ... Akumin is having some financial accounting issues of their own.  Management has a cease trade order from the OSC until the resolve their late financial reporting.  Akumin brought a problem forward related to some accounting it identified as of the purchase.

Hope that all gets reslovled quickly (November). 

Looks like one huge partnership brewing and if Akumin don't own or pay for the TULSA systems upfront ... I can see Akumin being interested in rolling out the systems.  Afterall, Akumin need to pay for the blockbuster acquisition and maybe Profound is a good vehicle to do so.

Thoughts ?


<< Previous
Bullboard Posts
Next >>